Wragge advises biopharmaceutical company arGEN-X on collaboration and alliance
Wragge Lawrence Graham & Co’s life sciences team has advised Netherlands- and Belgium-based biopharmaceutical company arGEN-X on its first collaboration with Bayer to discover and develop therapeutic antibody candidates and on a strategic alliance with Shire. Both deals were completed in the same week.
arGEN-X is a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases.
The company has announced the initiation of a collaboration with Bayer Pharma, leveraging its SIMPLE Antibody technology for the discovery and development of therapeutic antibodies. The collaboration centres on a novel approach to addressing complex targets across multiple therapeutic areas that are often intractable by existing antibody platforms.
With this new collaboration with Bayer, arGEN-X will apply its SIMPLE Antibody technology to multiple targets submitted by Bayer. The parties will work together to validate human antibody leads in disease-relevant models, with Bayer being responsible for further pre-clinical and clinical development and commercialisation of therapeutic antibody products.
Under the terms of the agreement, Bayer will pay arGEN-X an upfront technology access fee, research support and technical success-based milestones. Bayer will also pay clinical, regulatory and product sales-based milestones as antibody programmes progress through clinical development and registration.
Under the long-term strategic alliance with Shire, arGEN-X will bring its suite of human antibody discovery technologies to a partnership focused on multiple targets aligned with Shire’s therapeutic focus.
The multi-year initiative aimed at helping to augment the Shire development pipeline follows an initial research and development collaboration undertaken in March 2012. Shire will make a total investment of €15m (£12m) in arGEN-X, consisting of €3m in upfront cash and €12m in equity. In addition, it will fund the collaborative research programmes at arGEN-X and pay fees, clinical, regulatory and sales milestones and single-digit royalties on therapeutic product sales.
Wragge Lawrence Graham & Co partners Patrick Duxbury and Luke Kempton advised arGEN-X, working with chief executive officer Tim Van Hauwermeiren and vice-president of business development Debbie Allen. These agreements are the sixth and seventh transactions the team has undertaken for arGEN-X, including the original collaboration with Shire.
News from Wragge Lawrence Graham & Co
News from The Lawyer
Briefings from Wragge Lawrence Graham & Co
There seems to be a growing recognition that retaining the skills of the older worker makes sound business sense. But are we neglecting our younger potential workforce?
Benefit change exercises — what are the practical implications of the IBM case for trustees and employers?
The latest IBM case has implications for employers and trustees when considering changes to members’ pension benefits. But what implications?